|
N4 Pharma PLC on Monday said its Nuvec gene delivery system has successfully demonstrated targeted delivery of RNA to lung cancer cells in collaboration with US research institute SRI. Shares in N4 Pharma jumped 47% to 0.73 pence in London on Monday morning. The Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology said Nuvec particles, combined with SRI’s targeting molecules, delivered therapeutic RNA payloads specifically to non-small cell lung cancer cells. Precision targeting was achieved by functionalising Nuvec with a molecule binding to a protein which is highly expressed in epithelial cancers such as lung, breast, prostate and pancreatic cancers. The targeted Nuvec particles confirmed selective uptake, with RNA payloads delivered only by functionalised particles. N4 Pharma said this validates Nuvec as a differentiated delivery system for RNA therapies, with applications across cancers of high unmet need. Chief Executive Officer Nigel Theobold said: ‘These recent data from our collaboration with SRI are particularly exciting because they represent the first example of the use of Nuvec for the potential treatment of some of the most common and life-threatening cancers.’ N4 added that it has also shown Nuvec can target immune cells through mannose modification in its N4 101 programme, designed as an orally delivered therapy for inflammatory bowel disease. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
